Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis

Masako Nakanishi1, Christine Perret2, Emmanuelle J Meuillet3

  • 1Center for Molecular Medicine, University of Connecticut Health Center, Farmington, CT, USA, Inserm, U1016, département endocrinologie métabolisme et cancer, Institut Cochin, Paris, France and The University of Arizona Cancer Center, Department of Molecular and Cell Biology, Department of Nutritional Sciences, University of Arizona, Tucson, AZ, USA. Tucson, AZ, USA.

Carcinogenesis
|January 31, 2015
PubMed

Insights

Microsomal prostaglandin E2 synthase-1 (mPGES-1) deficiency worsens colon injury but unexpectedly compromises protection against adenoma formation. Inducible PGE2 plays a dual role in mucosal homeostasis and tumor growth.

Area of Science:

  • Oncology
  • Inflammation Research
  • Gastroenterology

Background:

  • Microsomal prostaglandin E2 synthase-1 (mPGES-1) is a key enzyme in inducible prostaglandin E2 (PGE2) production.
  • mPGES-1 is a potential target for cancer chemoprevention, with previous studies showing its genetic abrogation suppresses intestinal tumorigenesis.
  • The role of mPGES-1 in inflammation-associated colon cancer requires further elucidation.

Purpose of the Study:

  • To investigate the role of mPGES-1 in colon tumorigenesis within a dextran sulfate sodium (DSS)-induced inflammatory microenvironment.
  • To examine the impact of mPGES-1 deficiency on epithelial damage, regeneration, and adenoma formation in a preclinical model of colon cancer.

Main Methods:

  • Utilized Apc (Δ14/+) mice with either wild-type (D14:WT) or deleted (D14:KO) mPGES-1 genes.
  • Induced experimental colitis using dextran sulfate sodium (DSS) to create an inflammatory microenvironment.
  • Analyzed colonic mucosa for epithelial damage, cryptal structure formation, and adenoma progression.

Main Results:

  • mPGES-1 deficiency (D14:KO) increased sensitivity to acute mucosal injury and epithelial damage.
  • Unexpectedly, mPGES-1 deficiency compromised protection against adenoma formation, with lesions progressing more rapidly in D14:WT mice under specific DSS titration.
  • mPGES-1 was highly expressed in the intestinal stroma during DSS-induced ulceration, suggesting a role in inflammation and regeneration.

Conclusions:

  • Inducible PGE2, produced by mPGES-1, plays a complex and dual role in colon homeostasis and cancer.
  • PGE2 is critical for maintaining the colonic epithelial barrier and promoting regeneration.
  • This regenerative function is exploited during neoplastic transformation, where PGE2 contributes to the growth and expansion of early cryptal lesions in Apc (Δ14/+) mice.

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
3
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
2
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
3
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72